Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ads Therapeutics LLC currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This distribution indicates that each of the pending office actions is being reviewed by a different examiner and within a different technical unit, requiring the applicant to manage separate prosecution tracks without any overlap.
REILLY, SOPHIA JANE is the busiest examiner, with 1 pending office action. With 2 pending office actions and distinct examiners, the workload is decentralized, meaning that the prosecution of each application will be subject to the individual preferences and styles of different examiners. This lack of concentration requires a tailored approach for each matter currently pending at the USPTO.
The use of 2 distinct art units for the pending office actions suggests that the company's technology is being evaluated across different specialized groups. This necessitates an understanding of the specific cultures and policies within those distinct art units. Practitioners should be prepared to navigate different examiner relationships and art unit environments to successfully manage the current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | 1627 | §102§103§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 17927796 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS AND METHODS FOR TREATING ABNORMAL ANGIOGENESIS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 27d | Pending | Nov 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAds Therapeutics LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sophia Jane Reilly has the most, with 1 of Ads Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
